Navigation Links
Peregrine Reports Data Showing Bavituximab's Potential to Shrink Prostate Tumors
Date:9/7/2007

most commonly diagnosed cancer in men, accounting for 30 percent of all male cancers, and prostate cancer is second only to lung cancer as a leading cause of male cancer deaths. Currently, there is no cure for locally advanced or metastatic prostate cancer.

"We are delighted that bavituximab shrank resistant human prostate tumors in this study, an important new sign of its potential anti-cancer efficacy," said Steven W. King, president and CEO of Peregrine. "Preclinically, we have now shown that adding bavituximab equivalent antibodies to combination regimens significantly enhances the anti-tumor activity of cancer chemotherapy, of hormone deprivation therapy and of radiation therapy in prostate, breast, lung, brain and pancreatic cancers. The breadth of these potential applications supports many options for future clinical studies."

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is normally located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase Ib trial in advanced cancer patients to assess its safety in combination with common chemotherapy agents, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. A protocol for a Phase II trial of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC) is currently undergoing regulatory review in India. Bavituximab is also in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

This study, entitled "Vascular Targeting Antib
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Laboratories, Inc. (Nasdaq: CBRX ) ("Columbia" ... the three and six-month periods ended June 30, ... from the contribution of the Molecular Profiles services ... an anticipated and temporary decline in product revenues ... in one high-volume, high-margin market. Throughout the renewal ...
(Date:7/31/2014)... 31, 2014 Auxilium Pharmaceuticals, Inc. ... biopharmaceutical company, today announced that the Company will ... its partner Asahi Kasei Pharma Corporation (Asahi Kasei). ... submission of a regulatory application to the Japanese ... ® (collagenase clostridium histolyticum) for the treatment ...
(Date:7/30/2014)...  There is still time to share your ... Annual Institute for Supply Management ® – ... Management is open for submissions.  The annual competition ... of supply management by recognizing supply management organizations ... practices.  Entries are due August 22, 2014. ...
Breaking Medicine Technology:Columbia Laboratories Reports Second Quarter 2014 Financial Results 2Columbia Laboratories Reports Second Quarter 2014 Financial Results 3Columbia Laboratories Reports Second Quarter 2014 Financial Results 4Columbia Laboratories Reports Second Quarter 2014 Financial Results 5Columbia Laboratories Reports Second Quarter 2014 Financial Results 6Columbia Laboratories Reports Second Quarter 2014 Financial Results 7Columbia Laboratories Reports Second Quarter 2014 Financial Results 8Columbia Laboratories Reports Second Quarter 2014 Financial Results 9Columbia Laboratories Reports Second Quarter 2014 Financial Results 10Columbia Laboratories Reports Second Quarter 2014 Financial Results 11Columbia Laboratories Reports Second Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 4Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 5Institute for Supply Management, Michigan State University to recognize companies with excellent supply management practices 2
... Ltd. is pleased to announce that the Phase 2a clinical ... completed by January 21, 2011. Our company focuses ... market of androgenetic alopecia treatment and has developed a new ... androgenetic alopecia treatment was performed in 48 patients with mild-to-moderate ...
... 21, 2011 Cardiac Science Corporation , a ... and diagnostic cardiac monitoring devices that connect ... information systems, today announced it has completed certification with ... its HeartCentrix cardiology device connectivity solution for its resting ...
Cached Medicine Technology:R-Tech Ueno Completes Phase 2a Clinical Study of RK-023 to Treat Androgenetic Alopecia 2R-Tech Ueno Completes Phase 2a Clinical Study of RK-023 to Treat Androgenetic Alopecia 3Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 2Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 3Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 4Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 5
(Date:7/31/2014)... 2014 Many lawyers take up the law ... correct injustices, and preserve the rule of law. Upholding these ... lauded as crusading and exemplary by some, but reckless and ... whose seed might be planted within the legal system itself, ... punishment for an attorney - a referral to the bar's ...
(Date:7/31/2014)... New York, NY (PRWEB) July 31, 2014 ... managed IT solutions firm based in New York City, ... cabling infrastructure for the midtown Manhattan headquarters of a ... in corporate and investment banking. , Chico Ramnarayan, Chief ... with our client is an opportunity for us to ...
(Date:7/31/2014)... Loffler Companies, the leading business technology and services ... as a Microsoft Community Connections Partner of the Year ... 2014. , The Microsoft U.S. SMB Champions Club ... IT services and solutions to small and midsized business ... Champions Club member, Loffler has established a proven track ...
(Date:7/31/2014)... According to new research report "Meat Substitutes Market ... Tofu-Based Product, Tempeh, TVP, Seitan, Quorn, Others), by ... to 2019", defines and segments the global Meat ... the market value of sources, types, and categories ... driving and restraining factors for the global market ...
(Date:7/31/2014)... Angeles, California (PRWEB) July 31, 2014 ... program all year round to CEO Belina Calderon’s ... employment services and medical billing, 1Heart Caregiver Services, ... 1Heart Business Academy applauds the most recent resource ... Commerce Ambassador Glenn Bowie for sharing his expertise ...
Breaking Medicine News(10 mins):Health News:Supreme Court Press Petition of the Month for July 2014: Shutting Down Inconvenient Lawyers By Disbarment or Suspension 2Health News:Supreme Court Press Petition of the Month for July 2014: Shutting Down Inconvenient Lawyers By Disbarment or Suspension 3Health News:Global Bank Awards CRA with Network Infrastructure Contract 2Health News:Loffler Companies Named Microsoft Community Connections Partner of the Year Award Winner 2Health News:Loffler Companies Named Microsoft Community Connections Partner of the Year Award Winner 3Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 2Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 3Health News:1Heart Business Academy Applauds Resource Speaker and Trainer Los Angeles Area Chamber of Commerce Ambassador Glenn Bowie 2Health News:1Heart Business Academy Applauds Resource Speaker and Trainer Los Angeles Area Chamber of Commerce Ambassador Glenn Bowie 3Health News:1Heart Business Academy Applauds Resource Speaker and Trainer Los Angeles Area Chamber of Commerce Ambassador Glenn Bowie 4
... people with history of unprotected sex to have an ... transmission.// The announcement being the first case of such ... Thursday uncovered two clusters of HIV infections, HIV-1 subtype ... government scientists. They said that both the clusters found ...
... and China's growing strengths in medical research, British Prime ... 'global medical excellence cluster' comprising universities and drugs companies. ... southeast England to protect Britain's science base and boost ... latest of measures initiated by government functionaries while citing ...
... detection of colorectal cancer were almost four times as successful ... they// were more likely to spot polyps, according to ... a thin flexible tube with a tiny camera into the ... for abnormalities, including cancerous and pre-cancerous growths. ,On ...
... anti-rejection medications for kidney transplant recipients. It is well ... ,Long-term steroid use is associated with bone ... Therefore, much effort has been made toward decreasing, withdrawing ... organ transplantation. ,A new study in Clinical ...
... drivers suspected of driving while ‘over the limit,’ but subsequently ... tested positive// for a range of drugs, reveals research in ... call for routine drugs testing in all drivers who are ... ,The researchers base their findings on 2000 blood and urine ...
... Medicine and EXACT Sciences Corporation announced today the publication// ... DNA testing. The study found that the test demonstrated ... detection across all stages of cancer, regardless of the ... study confirms that stool-based DNA technologies can achieve high ...
Cached Medicine News:Health News:Britain Plans Medical Hub To Meet India, China Challenge 2Health News:Colonoscopies Can Help Prevent Colon Cancer; Only When Done Properly 2Health News:One in Three Drivers Under ‘The Limit’ for Alcohol Still Test Positive for Dru 2Health News:Study Results on Stool DNA Testing for Colon Cancer Announced 2
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
... The Self-Cath Closed System is ... a method for safe, simple catheterization ... urinary tract infections. It includes ... The new EasyOff tear tab ...
... Self-Cath Closed System is a latex-free ... for safe, simple catheterization designed to ... infections. It includes a 100% ... new EasyOff tear tab makes it ...
... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
Medicine Products: